Other substances

Celgosivir

An alpha-glucosidase I inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Celgosivir is an experimental alpha-glucosidase I inhibitor with potential activity against hepatitis C virus (NCIt).

Celgosivir on DrugBank
Celgosivir on PubChem
Celgosivir on Wikipedia


 

Structure image - Celgosivir

CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication
Spike protein Small molecule In vitro 		Vero E6 cells; SARS-CoV-2 isolate USA-WA1/2020 4.06

Prevents SARS-CoV-2-induced cell death and the virus' replication in a dose-dependent manner in vitro. It also decreases spike protein levels in infected cells.

 Sep/26/2020

AI-suggested references

Link Publication date
Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
Aug/14/2020
alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
Apr/01/2022
A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.
Jun/07/2021
Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2
Jul/20/2021
Export (.csv)